Tests gut bacteria and immune markers to predict treatment side effects
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This study looks at stool (gut microbiome) and blood immune marker results to predict who will get side effects from immunotherapy for advanced solid tumors. If your results suggest higher risk, it may help doctors choose safer or more personalized monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able to sign informed consent and take part voluntarily
- You must be able to give stool and blood samples at the scheduled times
- You must be 18 years or older
- You must have an advanced solid tumor that is not curable and be treated at Princess Margaret Cancer Centre
- You must be eligible to receive an immunotherapy (IO) combination
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at side effects from immune checkpoint inhibitors in people with solid tumors. It aims to understand why side effects happen and who might be at risk, so doctors can better manage them.
This trial looks at how the gut microbiome (the bacteria in your digestive system) relates to outcomes when you take standard immune “checkpoint” cancer medicines. If you’re eligible, they’ll collect stool samples while you receive treatment for certain cancers.
This trial studies whether changes in gut bacteria can help predict how well immunotherapy works for solid cancers. It also tests whether stool (fecal microbiota) from certain immunotherapy-responding people can improve outcomes for others who are not responding well.
This study tries to predict who is more likely to get serious side effects from immune checkpoint medicines used for solid tumors. You may help researchers by answering questionnaires before treatment and during follow-up, and by possibly storing sample specimens.
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
This study looks at how side effects happen in people receiving immune checkpoint inhibitor immunotherapy for solid cancers. It uses multiple types of tests to better understand these toxicities and may help improve safety and care in the future.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.